Celltrion / Pharmaceutical
Celltrion's Eyedenzelt Approved in Canada, Strengthens North American Market
Celltrion Eydenzelt Product Image Celltrion announced on the 28th that its biosimilar product for the ophthalmic disease treatment Eylea (active ingredient: aflibercept), named 'Eydenzelt (development name CT-P42)', has received marketing authorization from Health Canada.Eydenzelt has secured indica
2025.11.28